:. Food Industry News

Categories: Food Ingredients News | Product Innovations & Scientific Developments

BASF: The Combination of Lycopene and Vitamin E Inhibits Growth of Prostate Tumors

Source: BASF
19/04/2006

19 April 2006 - A New Research Study Demonstrates Health Benefit

The combination of lycopene and vitamin E suppresses tumor growth in mice by 73 percent and increases survival time by 40 percent. Lycopene alone tends to inhibit tumor growth and to prolong survival time as well, but less effectively (53 percent and 19 percent, respectively). A phase-II clinical trial with prostate cancer patients is ongoing to evaluate the health benefits of lycopene and vitamin E in humans.

Daily News Alerts

BASF announces the publication of its most recent scientific research study in the field of human nutrition in the upcoming May issue of the Journal of Nutrition. The publication is already available in the online edition of the journal. The study entitled „Combined Lycopene and Vitamin E Treatment Suppresses the Growth of PC-346C Human Prostate Cancer Cells in Nude Mice“ was a collaboration with leading researchers in the field of urology at the Erasmus University in Rotterdam, The Netherlands under the lead of Dr. Wytske van Weerden.

Prostate cancer is a major type of malignancy in men. While established risk factors for the disease exist including older age, family history of the disease, and race, there is ongoing search for dietary factors and micronutrients, which help lower the risk of contracting the disease. Epidemiologic studies have repeatedly associated a high intake of lycopene, the major tomato-carotenoid, and vitamin E with reduced prostate cancer risk and these two micronutrients are now among the most promising dietary components with regard to prostate cancer prevention.

BASF investigated how different doses of lycopene and vitamin E affect prostate tumor growth and whether a combination of lycopene and vitamin E exerts additional effects. Furthermore, the possibility to use PSA (prostate-specific antigen) levels in blood, which is an established clinical parameter for the disease, as a marker for tumor growth during lycopene and vitamin E intake was evaluated.

The PC-346C orthotopic mouse model of human prostate cancer, developed by the researchers in Rotterdam, is a useful model to monitor effects of diet on tumor growth. 54 mice were inoculated with prostate cancer cells and three days thereafter the mice were fed with either of the six following diets: lycopene (5 or 50 mg/kg body weight (BW)), vitamin E (5 or 50 mg/kg BW) or a mixture of lycopene and vitamin E (5 mg/kg BW each), or placebo. Tumor growth in prostate and levels of PSA in blood were assessed at regular intervals.

The BASF study shows that combined treatment with lycopene and vitamin E, at 5 mg/kg BW each, is most effective; growth of prostate tumors was suppressed by 73 percent and survival time was increased by 40 percent. There was a trend for 53 percent slower tumor growth and 19 percent increased survival time in the group receiving 5 mg/kg BW lycopene. The other treatments (vitamin E alone or lycopene at 50 mg/kg BW) did not have a significant effect on tumor growth.

Levels of PSA in blood increased with tumor growth in mice receiving placebo treatment. In the group receiving the combination of lycopene and vitamin E, PSA levels tended to be lower. The PSA index, a parameter used to demonstrate selected effects on PSA vs. tumor growth, did not differ between experimental groups indicating that PSA levels were proportional to tumor size regardless of the dietary supplementation with lycopene and vitamin E. Thus, lycopene and vitamin E are unlikely to interfere with PSA measurements, which is important for clinical diagnostics.

The study demonstrates a significant benefit of the combination of lycopene and vitamin E in inhibiting prostate tumor growth. In addition, PSA is corroborated as a marker for tumor burden for this treatment regimen. In order to test the effects of lycopene and vitamin E on tumor growth and PSA levels in humans, an exploratory phase-II prostate cancer trial is currently ongoing.

BASF Human Nutrition is a leading global partner for balanced and innovative nutrition to the dietary supplement, beverage and food industry. BASF Human Nutrition offers excellent quality ingredients for dietary supplements, beverages and foods produced with modern state-of-the-art technologies. BASF Human Nutrition offers outstanding technical services and scientific expertise to meet the highest demands and to deliver the best value to the industry. Premium formulations are a key strength that has made BASF a leader in the industry.



GO   View more articles on this subject


More Alerts from 20/04/2006


Email This Article To A Colleague     Print A Copy Of This Page
 
 
 
 
FLEXNEWS - Business News for the Food Industry

About Us | Contact Us | Terms & Conditions | Privacy Policy
 
Daily News Alerts
Related Items
European Food Safety Authority Rates BASF's LycoVit...
US Chemical Firm Hawkin's to Expand Lactate and Other...
EU Commission Clears Proposed Acquisition of GBI UK...
CHS Reports Record Net Income of $657.6 Million Through...
Ashland to Acquire Hercules
Penford Reports Third Quarter 2008 Earnings
Rousselot Acquires PEPTAN
Rohm and Haas Reaches Accord to be Acquired by The...
New Plant Polysaccharide for Bread
France: Lesaffre Normandie to Invest 8 Mln Euro in...

More in Food Industry News
Nigerian Stock Exchange Suspends Trading on Cadbury's...
US: Coke Consolidated Cuts 350 Jobs
Finland: Huhtamaki Sees Profit Falling, Plans Price...
EU Restarts Merger Review of Planned Associated British...
France: Belvedere Says Seeking Solution with Note Holders
Sensient Technologies Corporation Reports Earnings...
EU Extends Review of Arsenal Capital/DSM Deal
Parmalat Says in Talks with UniCredit, No Deal Yet
Brazil Aluminum Cans Sector to Grow, Invest in 2008
Unicredit to Pay 300 Mln Euros to Parmalat

Top Headlines
Nigerian Stock Exchange Suspends Trading on Cadbury's...
US: Coke Consolidated Cuts 350 Jobs
EU Restarts Merger Review of Planned Associated British...
France: Belvedere Says Seeking Solution with Note Holders
EU Extends Review of Arsenal Capital/DSM Deal
Brazil Aluminum Cans Sector to Grow, Invest in 2008
Unicredit to Pay 300 Mln Euros to Parmalat
US Dairy Group to Cut Herd Size to Lift Milk Prices
Sligro Food Group's First Half Net Profit up 11.3%...
Starbucks Discloses Full List of U.S. Store Closures
Container Shortages Preventing US Ag Exporters from...
U.S. Barley Producers' Reactions to Anheuser Busch...
Ugandan Coffee May Disappear in 30 Years - Oxfam
Mars Teams Up with USDA to Improve Cacao Genetics for...
Delhaize Group Updates 2008 Full-Year Outlook And Releases...
Maple Leaf Foods Purchases Additional Canada Bread...
EU Commission Approves Proposed Acquisition of V&S...
European Commission Opens In-Depth Investigation into...
U.S. Regulators Lifting Tomato Salmonella Warning
Russian Prodimex Subsidiary to Invest USD170 Million...
Californian Speciality Coffee Company Peet's Sees Expansion...
Safeway Inc. Announces Second-Quarter 2008 Earnings
Coca-Cola Aims for USD 400-500 Mln in Yearly Savings...
The Coca-Cola Company Reports Second Quarter and Half...
Coca-Cola Enterprises Inc. Reports Second-Quarter 2008...


 


FLEXNEWS 2008 - All rights reserved
ISSN 1950-6228